In the group of melanoma patients treated with combined BRAF and MEK inhibitors, MICA+-EVs were detected only in one out of six patients and sULBP2 showed again a decrease after starting the treatment in one patient while an increase at later time points in other two patients, corresponding with time points when disease progression was detected in those two patients. This evidence concerns the gene BRAF and melanoma.